

# Maternal adipo-enteric-pancreatic- brain crosstalk in pregnancy and fetal growth



**G. VALSAMAKIS**

**ENDOCRINOLOGIST ENDOCRINE UNIT,  
EVGENIDEION&ARETAIEION HOSPITALS,  
ATHENS, GREECE**

- **VISITING ASSOCIATE CLINICAL  
PROFESSOR WARWICK MEDICAL SCHOOL,  
UK**
- **EUROPEAN SCOPE FELLOW IN OBESITY**

- **Endometrial environment in pregnancy**
- **Insulin resistance in pregnancy**
  - Role of maternal obesity
  - Role of glucose
  - Role of the Adipo-Enteric-Insular axis
- **Fetal anthropometry parameters**
- **Gut hormones in pregnancy**
  - GLP-1, Ghrelin
- **Insular hormones in pregnancy**
  - Insulin, Glucagon, Amylin
- **Perspectives-Conclusions**

# FETUS

Fetal genome

Imprinted genes alter placental function  
Demand for nutrients

*Placental function promotes fetal growth*

*Maternal constraint limits fetal growth*

# PLACENTA

# MOTHER

Placental trophoblast invasion

↑ Placental blood flow

↑ Growth of placenta

↑ Hormone production  
↑ Placental transporters  
Glucocorticoid barrier

Maternal genome ↔ Maternal environment

Maternal development

Maternal pregnancy state

↑ Uterine artery flow

Metabolism & behaviour

↑ Nutrient intake


- ← Maternal health
- ← Maternal smoking
- ← Maternal nutrition
- ← Maternal hypoxia


*Maternal pregnancy state promotes placental growth*


# ***Factors affecting the endometrial environment***



1. Changes in maternal metabolism,
2. dietary habits,
3. anthropometrics,
4. psychological behavioral and personality factors.
5. Placental growth and function.
6. External environmental factors.
7. The interaction of the triad: mother-placenta-fetus







## Fetal Programming

Process whereby a stimulus applied *in utero* establishes a **permanent response** in the fetus leading to enhanced susceptibility to later disease.



Lucas A. Arch. Dis. Childhood 1995

# **Fetal metabolic adaptations... so far**




**Hyperinsulinaemia**





**Hyperleptinaemia**

**Hypercortisolism**

# Birth weight and overall postpartum mortality



# Birth weight and GDM prevalence



# Neonatal abdominal circumference



a measure of liver volume and adiposity

reflects the adipose-energy deposits of the neonate

a vital index for the beginning of the neonatal life and predictive of its future growth and metabolic health

# Fetal outcomes and maternal pre-pregnancy weight (BMI)



- Large for gestational age
- Birth weight >4000gr
- Neonatal hypoglycemia
- Respiratory distress syndrome
- Jaundice
- Perinatal mortality
- Congenital malformations



# Pregravid maternal BMI and neonatal body composition (Sewell et al.)



<b>Pregravid BMI</b>	<b>BMI&gt;25</b>	<b>BMI&lt;25</b>	<b>P-value</b>
Birth weight (gr)	3436 ± 567	3284 ± 534	0.051
LBM (gr)	3023 ± 410	2951 ± 406	0.22
Fat mass (gr)	416 ± 221	334 ± 179	0.008
Body fat (%)	11.6 ± 4.7	9.7 ± 4.3	0.006
Maternal weight gain	6.3 ± 3.4	6.9 ± 2.4	0.001



# Prevalence of obesity (BMI > 95% age and gender) in offspring of obese women



<b>Prevalence of obesity</b>	<b>age</b>
9.5%	2
12.5%	3
14.8%	4
(Whitaker et al. Pediatrics)	

# Adipose tissue as an endocrine organ



## Adipose Tissue




- ▶ FFA
- ▶ Leptin
- ▶ Angiotensinogen
- ▶ Resistin
- ▶ CRP
- ▶ TNF- $\alpha$
- ▶ PAI-1
- ▶ Serum amyloid-A
- ▶ IL-6, IL-1
- ▶ Estrogens
- ▶ Cortisol
- ▶ Visfatin
- ▶ SAA
- ▶ MCP-1
- ▶ RBP-4

Modified from Caballero AE. *Curr Diab Rep.* 2004;4:237-246.

# Adipocytokines in pregnancy

	Adipocyte	SVF	Placenta
TNF- $\alpha$	+	+ + +	+
IL-6	+	+	+
IL-1b		+ +	
IL-8	+	+ +	+
IL-1Ra	+	+ +	+
IL-10	+	+ +	+
Leptin	+ +	0	+
Adiponectin	+ +	0	-
Resistin	0	+ +	+
MCP-1	+	+ +	+
MIF	+ +	+	+
VEGF	+	+ +	+
PAI-1	+	+ +	+
Cathepsin S	+	+ +	+

# Adipose tissue deposition during pregnancy



*The* **NEW ENGLAND**  
**JOURNAL** *of* **MEDICINE**

ESTABLISHED IN 1812

MAY 8, 2008

VOL. 358 NO. 19

## Hyperglycemia and Adverse Pregnancy Outcomes

The HAPO Study Cooperative Research Group\*


### **CONCLUSIONS**

Our results indicate strong, continuous associations of maternal glucose levels below those diagnostic of diabetes with increased birth weight and increased cord-blood serum C-peptide levels.


# HAPO study

◆ Fasting glucose    ■ 1-Hr glucose    ▲ 2-Hr glucose


**A Birth Weight >90th Percentile**




**B Primary Cesarean Section**




**C Clinical Neonatal Hypoglycemia**




**D Cord-Blood Serum C Peptide >90th Percentile**






# Adipose-**enteric**-insular-brain crosstalk









**Cholecystikinin**

Gall bladder contraction  
Gastrointestinal motility  
Pancreatic exocrine secretion

**Secretin**

Pancreatic exocrine secretion

**GIP**

Incretin activity

**Motilin**

Gastrointestinal motility

**Ghrelin**

Hunger

Growth hormone release

**Gastrin**

Acid secretion

**Insulin and glucagon**

Glucose homeostasis

**Pancreatic polypeptide**

Gastric motility

Satiation

**Amylin**

Glucose homeostasis

Gastric motility

**GLP-1**

Incretin activity

Satiation

**GLP-2**

Gastrointestinal motility and growth


**Oxyntomodulin**

Satiation

Acid secretion

**PYY<sub>3-36</sub>**

Satiation



# Aim of our study



is the detection of connections between markers of maternal and fetal metabolism during pregnancy with the subsequent growth and metabolism during neonatal and childhood life.

# methodology



## 1) Maternal anthropometrics-haemodynamics

- weight, height, BMI, waist, hip, skinfolds, BP, pulses

## 2) OGTT 75 gr



- collection insulin, glucose at 0, 5, 15, 30, 60, 90, 120 min
- peptides-hormones at 0, 30, 60, 120 min

## 3) Fetal ultrasound

## 4) Cord blood peptides

## 4) Birth weight and waist

# visfatin



# Adipocytokines and insulin sensitivity

**Table 3. Statistically significant correlations among carbohydrate metabolism variables and adipocytokines.<sup>a</sup>**

<b>1st trimester</b>								
Variable 1	1st PHIS	1st PHIS	2nd PHIS	2nd PHIS	ΔAUCI	ΔAUCI	ISI	ISI
Variable 2	Leptin	HsCRP	Leptin	hsCRP	Leptin	hsCRP	Leptin	hsCRP
r-Spearman	0.56	0.53	0.53	0.5	0.48	0.68	-0.54	-0.5
<b>2nd trimester</b>								
Variable 1		1st PHIS		2nd PHIS				ΔAUCI
Variable 2		Leptin		Leptin				Leptin
r-Spearman		0.43		0.45				0.48

<sup>a</sup> The r-Spearman correlation is significant at  $P < 0.05$ .

**Table 5. Backwards multiple regression analysis for dependent variable ISI 2nd trimester.<sup>a</sup>**

	Coefficient	SE of coefficient	P value
Visfatin 1st trimester	1.018	0.024	0.015
HsCRP 1st trimester	0.157	0.024	0.099

<sup>a</sup> The term "coefficient" is the generally used term for the effect of each predictor (independent variable) on the respective dependent variable in a linear regression analysis.

# Maternal Serum Visfatin at 11–13 Weeks of Gestation in Gestational Diabetes Mellitus

**Table 2.** Median (IQR) of maternal serum concentration of adiponectin and visfatin in the outcome groups.

	Nondiabetic controls	GDM
n	300	100
Adiponectin		
μg/L	12 035 (8595–7 085)	7591 (4552–11 059) ↓
MoM	1.02 (0.70–1.29)	0.66 (0.50–0.92) <sup>a</sup> ↓
Visfatin		
μg/L	0.89 (0.47–1.71)	1.20 (0.63–2.55) ↑
MoM	1.00 (0.53–1.92)	1.34 (0.70–2.87) <sup>a</sup> ↑

<sup>a</sup>  $P < 0.05$ . Comparisons between groups by Mann–Whitney  $U$ -test.

**Table 3.** Performance of screening for GDM by maternal factors, maternal serum adiponectin MoM, visfatin MoM, and their combinations.

Screening test	AUROC <sup>a</sup> (95% CI)	Detection rate for false-positive rate of 10% (95% CI)
Maternal factors	0.828 (0.777–0.878)	58.0 (48.2–67.2)
Maternal factors plus		
Adiponectin	0.854 (0.807–0.900)	66.0 (56.3–74.5)
Visfatin	0.825 (0.774–0.876)	64.0 (54.2–72.7)
Adiponectin and visfatin	0.855 (0.808–0.901)	68.0 (58.3–76.3)

<sup>a</sup> AUROC, area under the ROC curve.

# Associations of maternal adipocytokines




1 <sup>st</sup> trimester					2 <sup>nd</sup> trimester	3 <sup>rd</sup> trimester
Variable 1	Maternal visfatin	Materna visfatin	materna leptin	Maternal hip	Maternal ghrelin active	Maternal visfatin
Variable 2	Maternal % fat	Maternal hip	maternal weight	birth weight	birth waist	birth weight
r-Spearman	-0.75	-0.61	0.85	0.52	0.75	-0.72




**ΠΟΙΟΙ ΑΝΘΡΩΠΟΜΕΤΡΙΚΟΙ  
ΚΑΙ ΒΙΟΧΗΜΙΚΟΙ  
ΠΑΡΑΓΟΝΤΕΣ ΤΗΣ ΜΗΤΕΡΑΣ  
ΣΥΣΧΕΤΙΖΟΝΤΑΙ ΜΕ ΤΗΝ  
ΑΝΑΠΤΥΞΗ ΚΑΙ ΤΟ  
ΜΕΤΑΒΟΛΙΣΜΟ ΤΟΥ  
ΕΜΒΡΥΟΥ**


# 1<sup>st</sup> trimester maternal weight and cord blood c-peptide ( $p=0.035$ , $r=0.74$ ). (Valsamakis et al.submitted)





# First trimester maternal hip vs birthweight ( $p=0.026$ , $r=0.52$ )



# 1<sup>st</sup> trimester maternal weight and cord blood visfatin ( $p=0.049$ , $r=-0.67$ )





# Leptin-ghrelin interactions: hypothalamus



- active ghrelin
- adipocytokine leptin at high levels produces satiation, appetite control system.
- both “inform” the corresponding hypothalamic centers about the nutritional status and the level of energy storage
- (Heppner KM et al. Methods in Enzymology 2012)

# AMPK



- AMPK is an intracellular energy sensor and energy regulator
- switching off ATP-consuming pathways
- switching on ATP-producing pathways such as glucose uptake and fatty acid oxidation

# **Leptin-ghrelin AMPK balance: hypothalamus (2)**



- 1) Negative energy balance is associated with:
  - increase of plasma ghrelin,
  - Increase of hypothalamic AMPK
  - Increase of food intake
  
- 2) Incr. leptin leads to suppressed hypothalamic AMPK activity and contributes to restriction of food intake
  
- (Stark R et al. Mol Cel Endocrinology 2013)


# Ghrelin and AMPK: visceral fat




in mice active ghrelin acting through its GHSR receptor :

- stimulates the hypothalamic AMP-activated protein kinase (AMPK) activity
- inhibits (AMPK) activity in the liver and visceral fat (mesenteric fat)
- (Lim CT et al. Mol Cel Endocrinology 2013)

**second trimester maternal active ghrelin levels with neonatal  
birth waist circumference (p=0.04, r=0.75)  
(Valsamakis et al. submitted)**



**third trimester maternal leptin levels with neonatal birth waist circumference**  
**( $p=0.027$ ,  $r=-0.81$ ) (submitted)**



# Ghrelin and insulin secretion





- ghrelin is expressed in pancreatic cells
- inhibits maternal glucose-driven insulin release in humans
- Resulting in increased maternal circulating glucose levels

# Third trimester maternal plasma active ghrelin levels (submitted)




- correlated negatively with:
  1. percent total neonatal body fat ( $p=0.04$ ,  $r=-0.94$ ),
  2. cord blood insulin levels ( $p=0.04$ ,  $r=-0.829$ )
  3. fetal HOMAR ( $p=0.021$ ,  $r=-0.829$ ).
  
- (Valsamakis et al. submitted)





**2<sup>nd</sup> trimester  
GLP-1 and  
U/S fetal  
abdomen**

**2<sup>nd</sup> trimester  
GLP-1 and  
neonatal  
birth weight**



## Amylin,

1. is a 37-residue peptide hormone secreted by pancreatic  $\beta$ -cells at the same time as insulin (in a roughly 100:1 ratio).
2. functions as part of the endocrine pancreas and contributes to glycemic control.
3. slows gastric emptying, promote satiety, inhibit secretion of glucagon during hyperglycemia, and therein reduce the total insulin demand.
4. Rodent amylin knockouts are known to fail to achieve the normal anorexia following food consumption. ..

# Gut hormones associations



1 <sup>st</sup> trimester							2 <sup>nd</sup> trimester		
variable 1	Ghrelin active	PP	Ghrelin active	PP	Ghrelin active	PYY total	leptin	Glucagon	glucagon
Variable 2	GLP-1 active	GLP-1 active	PP	PYY total	GIP	GLP-1	GIP	Amylin active	adiponectin
r-Spearman	0.55	0.45	0.43	0.54	0.5	0.46	-0.75	-0.45	-0.93
3 <sup>rd</sup> trimester									
variable 1	Ghrelin active	Ghrelin active	glucagon						
Variable 2	GLP-1 active	GIP	PYY total						
r-Spearman	0.69	-0.47	-0.76						

# Best predictor of insulin resistance change: maternal visfatin change



The longitudinal regression model taking in consideration all three trimesters revealed that visfatin change was the best positive and negative predictor of insulin resistance (HOMAR) ( $p=0.0002$ ,  $t\text{-value}=4.48$ ) and sensitivity (ISI) ( $p=0.002$ ,  $t\text{-value}=-3.65$ ) changes, respectively, during pregnancy among active ghrelin, active GLP-1, GIP, glucagon, PP, total PYY, active amylin, leptin and adiponectin levels

# Best predictor of maternal weight change: maternal active amylin change



The longitudinal regression model taking in consideration all three trimesters revealed that active amylin change during pregnancy was the best negative predictor ( $p=0.02$ ,  $t\text{-value}=-2.41$ ) of maternal weight change during pregnancy among active ghrelin, active GLP-1, GIP, glucagon, PP, total PYY, visfatin, leptin and adiponectin levels.

# Best birth weight predictor: early adiposity



Stepwise multiple regression analysis revealed that 1<sup>st</sup> trimester visfatin levels were the best negative predictor ( $p=0.017$ ,  $\beta=-1.23$ ) together with leptin ( $p=0.022$ ,  $\beta=-1.09$ ) levels of birth weight among 1<sup>st</sup> trimester plasma levels of active ghrelin, active GLP-1 total PYY, active amylin, glucagon, PP and adiponectin levels.

# Best birth waist circumference predictor: 2<sup>nd</sup> trimester maternal circulating ghrelin



Stepwise multiple regression analysis revealed that 2<sup>nd</sup> trimester active ghrelin levels were the best positive predictor ( $p=0.03$ ,  $\beta=0.84$ ) of neonatal waist circumference among 2<sup>nd</sup> trimester plasma levels of active GLP-1, total PYY, GIP, active amylin, PP, visfatin, leptin and adiponectin

# Best cord blood insulin: maternal ghrelin



- Stepwise multiple regression analysis revealed that third trimester maternal circulating active ghrelin levels were the best negative predictor ( $p=0.02$ ,  $\beta=-0.99$ ) of cord blood insulin levels among third trimester maternal weight and fasting plasma leptin, active GLP1 and total PYY levels

# Conclusions (1)



- an association among first trimester maternal adipose tissue (as represented by maternal weight and maternal serum visfatin levels of first trimester) with:
  1. fetal insulin secretion
  2. birth weight

# Conclusions (2)



- ghrelin, increases maternal appetite
- might increase nutrient supplies to the fetus resulting to its positive energy balance.
- It might also contribute to the visceral storage of energy supplies *via* the inhibition of the visceral AMPK activity.

# Conclusions (3)



- Maternal ghrelin ensures adequate fasting glucose and nutrient supplies to the fetus.
- fetal insulin secretion decreases
- overall fetal adipose tissue deposition is avoided

# Conclusions: hypothesis



- it seems that maternal adipo-entero-pancreatic hormones together with the probable placental secretion of certain among them might be involved in an interplay during pregnancy including maternal adipose tissue, appetite and insulin resistance, and fetal adipose tissue, growth and metabolism resulting to the birth of a healthy neonate sufficiently equipped to deal with a possibly hostile environment during the first days of its life.

# clinicalobesity

translating research and evidence into clinical practice

**VOLUME 1 ISSUE 1 FEBRUARY 2011**

Editor-in-Chief: **Nick Finer**

## **IN THIS ISSUE**

*Clinical Obesity* – a new journal

Bariatric surgery for children and adolescents

Weight loss for obstructive sleep apnoea

Very low-energy diets

Weight management for osteoarthritis

ISSN 1758-8103

 **WILEY-BLACKWELL**

Published on behalf of 

# Ευχαριστιες



- Αν Καθηγητή κο Μαστοράκο
- **Professor S Kumar, Warwick Medical School, UK**